News

Minaris Regenerative Medicine is proud to share current and past news and announcements from its over twenty years of experience. Please see below for our press releases and announcements.

Global Media Contact
Almut Windhager, Ph.D.
press@rm.minaris.de

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.

July 21, 2021

Minaris will be the commercial manufacturer in Europe for Skysona™, bluebird bio's gene therapy for CALD

MUNICH, Germany – July 21, 2021 - Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing organization (CDMO) for the cell and gene therapy industry, will be the commercial manufacturer in Europe for SkysonaTM (elivaldogene autotemcel, Lenti-D™), a product of bluebird bio, Inc. Today, the European Commission (EC) has granted marketing authorization for ...

All Posts

Minaris will be the commercial manufacturer in Europe for Skysona™, bluebird bio's gene therapy for CALD

Subscribe to Our Email Distribution List